AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NRIX

Hansen Gwenn sold $90K of NRIX

Hansen Gwenn (Chief Scientific Officer) sold 3,847 shares of Nurix Therapeutics, Inc. (NRIX) at $23.38 on 2026-07-30.

Original reporting
SEC EDGAR · Hansen Gwenn
Published Jul 30, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
medium confidence
Mentioned
$NRIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The only new information is the insider’s sale details (shares, price, total value, and remaining holdings).

02

Market read

Traders may monitor insider activity, but this specific disclosure does not introduce new company fundamentals or catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still lacks context on whether the sale was tax, diversification, or planned personal liquidity.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-30 (after-hours)

Background

The article is a SEC Form 4 insider transaction disclosure for Nurix Therapeutics, Inc.

Company-level read

Ticker impact

$NRIXNeutralMedium confidence
Context

Nurix Therapeutics CSO Hansen Gwenn filed a Form 4 open-market sale of 3,847 shares at $23.3828 on 2026-07-30.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal from a single non-10b5-1 sale.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no accompanying company news, guidance, or operational change.

Market effects

Sector

Minimal; insider sale in a biotech does not, by itself, reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity events and may not reflect negative fundamentals, especially without a stated reason.

Key entities

  • issuer
    Nurix Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Hansen Gwenn

    Chief Scientific Officer who sold 3,847 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

tradingview.com
$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

genengnews.com
$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

investing.com